



Sen. Karina Villa

Filed: 3/3/2023

10300SB1497sam001

LRB103 26129 JDS 58560 a

1 AMENDMENT TO SENATE BILL 1497

2 AMENDMENT NO. _____. Amend Senate Bill 1497 by replacing
3 everything after the enacting clause with the following:

4 "Section 5. The Nursing Home Care Act is amended by
5 changing Sections 1-112, 2-106, and 2-106.1 as follows:

6 (210 ILCS 45/1-112) (from Ch. 111 1/2, par. 4151-112)

7 Sec. 1-112. "Emergency" means a situation, physical
8 condition, or one or more practices, methods, or operations
9 which present imminent danger of death or serious physical or
10 mental harm to residents of a facility and are clinically
11 documented in the resident's medical record.

12 (Source: P.A. 81-223.)

13 (210 ILCS 45/2-106) (from Ch. 111 1/2, par. 4152-106)

14 Sec. 2-106. Restraints.

15 (a) For purposes of this Act, ~~(i)~~ a physical restraint is

1 any manual method or physical or mechanical device, material,
2 or equipment attached or adjacent to a resident's body that
3 the resident cannot remove easily and restricts freedom of
4 movement or normal access to one's body, and . ~~Devices used for~~
5 ~~positioning, including but not limited to bed rails, gait~~
6 ~~belts, and cushions, shall not be considered to be restraints~~
7 ~~for purposes of this Section; (ii) a chemical restraint is any~~
8 drug used for discipline or convenience and not required to
9 treat medical symptoms.

10 Devices used for positioning, including, but not limited
11 to, bed rails, gait belts, and cushions, shall not be
12 considered to be physical restraints for purposes of this Act
13 unless the device is used to restrain or otherwise limit the
14 patient's freedom to move. The need for a device used for
15 positioning must be physically demonstrated by the resident
16 and documented in the resident's care plan. The physically
17 demonstrated need of the resident for a device used for
18 positioning must be revisited in every comprehensive
19 assessment of the resident.

20 The Department shall by rule, designate certain devices as
21 restraints, including at least all those devices which have
22 been determined to be restraints by the United States
23 Department of Health and Human Services in interpretive
24 guidelines issued for the purposes of administering Titles
25 XVIII and XIX of the Social Security Act.

26 (b) Neither restraints nor confinements shall be employed

1 for the purpose of punishment or for the convenience of any
2 facility personnel. No restraints or confinements shall be
3 employed except as ordered by a physician who documents the
4 need for such restraints or confinements in the resident's
5 clinical record.

6 (c) A restraint may be used only with the informed consent
7 of the resident, the resident's guardian, or other authorized
8 representative. A restraint may be used only for specific
9 periods, if it is the least restrictive means necessary to
10 attain and maintain the resident's highest practicable
11 physical, mental or psychosocial well-being, including brief
12 periods of time to provide necessary life-saving treatment. A
13 restraint may be used only after consultation with appropriate
14 health professionals, such as occupational or physical
15 therapists, and a trial of less restrictive measures has led
16 to the determination that the use of less restrictive measures
17 would not attain or maintain the resident's highest
18 practicable physical, mental or psychosocial well-being.
19 However, if the resident needs emergency care, restraints may
20 be used for brief periods to permit medical treatment to
21 proceed unless the facility has notice that the resident has
22 previously made a valid refusal of the treatment in question.

23 (d) A restraint may be applied only by a person trained in
24 the application of the particular type of restraint.

25 (e) Whenever a period of use of a restraint is initiated,
26 the resident shall be advised of his or her right to have a

1 person or organization of his or her choosing, including the
2 Guardianship and Advocacy Commission, notified of the use of
3 the restraint. A recipient who is under guardianship may
4 request that a person or organization of his or her choosing be
5 notified of the restraint, whether or not the guardian
6 approves the notice. If the resident so chooses, the facility
7 shall make the notification within 24 hours, including any
8 information about the period of time that the restraint is to
9 be used. Whenever the Guardianship and Advocacy Commission is
10 notified that a resident has been restrained, it shall contact
11 the resident to determine the circumstances of the restraint
12 and whether further action is warranted.

13 (f) Whenever a restraint is used on a resident whose
14 primary mode of communication is sign language, the resident
15 shall be permitted to have his or her hands free from restraint
16 for brief periods each hour, except when this freedom may
17 result in physical harm to the resident or others.

18 (g) The requirements of this Section are intended to
19 control in any conflict with the requirements of Sections
20 1-126 and 2-108 of the Mental Health and Developmental
21 Disabilities Code.

22 (Source: P.A. 97-135, eff. 7-14-11.)

23 (210 ILCS 45/2-106.1)

24 Sec. 2-106.1. Drug treatment.

25 (a) A resident shall not be given unnecessary drugs. An

1 unnecessary drug is any drug used in an excessive dose,
2 including in duplicative therapy; for excessive duration;
3 without adequate monitoring; without adequate indications for
4 its use; or in the presence of adverse consequences that
5 indicate the drugs should be reduced or discontinued. The
6 Department shall adopt, by rule, the standards for unnecessary
7 drugs contained in interpretive guidelines issued by the
8 United States Department of Health and Human Services for the
9 purposes of administering Titles XVIII and XIX of the Social
10 Security Act.

11 (b) State laws, regulations, and policies related to
12 psychotropic medication are intended to ensure psychotropic
13 medications are used only when the medication is appropriate
14 to treat a resident's specific, diagnosed, and documented
15 condition and the medication is beneficial to the resident, as
16 demonstrated by monitoring and documentation of the resident's
17 response to the medication.

18 (b-3) Except in the case of an emergency, psychotropic
19 medication shall not be administered without the informed
20 consent of the resident or the resident's surrogate decision
21 maker. Psychotropic medication shall only be given in both
22 emergency and nonemergency situations if the diagnosis of the
23 resident supports the benefit of the medication and clinical
24 documentation in the resident's medical record supports the
25 benefit of the medication over the contraindications related
26 to other prescribed medications. "Psychotropic medication"

1 means medication that is used for or listed as used for
2 psychotropic, antidepressant, antimanic, or antianxiety
3 behavior modification or behavior management purposes in the
4 latest editions of the AMA Drug Evaluations or the Physician's
5 Desk Reference. "Emergency" has the same meaning as in Section
6 1-112 of the Nursing Home Care Act. A facility shall (i)
7 document the alleged emergency in detail, including the facts
8 surrounding the medication's need, and (ii) present this
9 documentation to the resident and the resident's
10 representative. The Department shall adopt, by rule, a
11 protocol specifying how informed consent for psychotropic
12 medication may be obtained or refused. The protocol shall
13 require, at a minimum, a discussion between (i) the resident
14 or the resident's surrogate decision maker and (ii) the
15 resident's physician, a registered pharmacist, or a licensed
16 nurse about the possible risks and benefits of a recommended
17 medication and the use of standardized consent forms
18 designated by the Department. The protocol shall include
19 informing the resident, surrogate decision maker, or both of
20 the existence of a copy of: the resident's care plan; the
21 facility policies and procedures adopted in compliance with
22 subsection (b-15) of this Section; and a notification that the
23 most recent of the resident's care plans and the facility's
24 policies are available to the resident or surrogate decision
25 maker upon request. Each form designated or developed by the
26 Department (i) shall be written in plain language, (ii) shall

1 be able to be downloaded from the Department's official
2 website or another website designated by the Department, (iii)
3 shall include information specific to the psychotropic
4 medication for which consent is being sought, and (iv) shall
5 be used for every resident for whom psychotropic drugs are
6 prescribed. The Department shall utilize the rules, protocols,
7 and forms developed and implemented under the Specialized
8 Mental Health Rehabilitation Act of 2013 in effect on the
9 effective date of this amendatory Act of the 101st General
10 Assembly, except to the extent that this Act requires a
11 different procedure, and except that the maximum possible
12 period for informed consent shall be until: (1) a change in the
13 prescription occurs, either as to type of psychotropic
14 medication or an increase or decrease in dosage, dosage range,
15 or titration schedule of the prescribed medication that was
16 not included in the original informed consent; or (2) a
17 resident's care plan changes. The Department may further amend
18 the rules after January 1, 2021 pursuant to existing
19 rulemaking authority. In addition to creating those forms, the
20 Department shall approve the use of any other informed consent
21 forms that meet criteria developed by the Department. At the
22 discretion of the Department, informed consent forms may
23 include side effects that the Department reasonably believes
24 are more common, with a direction that more complete
25 information can be found via a link on the Department's
26 website to third-party websites with more complete

1 information, such as the United States Food and Drug
2 Administration's website. The Department or a facility shall
3 incur no liability for information provided on a consent form
4 so long as the consent form is substantially accurate based
5 upon generally accepted medical principles and if the form
6 includes the website links.

7 Informed consent shall be sought from the resident. For
8 the purposes of this Section, "surrogate decision maker" means
9 an individual representing the resident's interests as
10 permitted by this Section. Informed consent shall be sought by
11 the resident's guardian of the person if one has been named by
12 a court of competent jurisdiction. In the absence of a
13 court-ordered guardian, informed consent shall be sought from
14 a health care agent under the Illinois Power of Attorney Act
15 who has authority to give consent. If neither a court-ordered
16 guardian of the person nor a health care agent under the
17 Illinois Power of Attorney Act is available and the attending
18 physician determines that the resident lacks capacity to make
19 decisions, informed consent shall be sought from the
20 resident's attorney-in-fact designated under the Mental Health
21 Treatment Preference Declaration Act, if applicable, or the
22 resident's representative.

23 In addition to any other penalty prescribed by law, a
24 facility that is found to have violated this subsection, or
25 the federal certification requirement that informed consent be
26 obtained before administering a psychotropic medication, shall

1 thereafter be required to obtain the signatures of 2 licensed
2 health care professionals on every form purporting to give
3 informed consent for the administration of a psychotropic
4 medication, certifying the personal knowledge of each health
5 care professional that the consent was obtained in compliance
6 with the requirements of this subsection.

7 (b-5) A facility must obtain voluntary informed consent,
8 in writing, from a resident or the resident's surrogate
9 decision maker before administering or dispensing a
10 psychotropic medication to that resident. When informed
11 consent is not required for a change in dosage, the facility
12 shall note in the resident's file that the resident was
13 informed of the dosage change prior to the administration of
14 the medication or that verbal, written, or electronic notice
15 has been communicated to the resident's surrogate decision
16 maker that a change in dosage has occurred.

17 (b-10) No facility shall deny continued residency to a
18 person on the basis of the person's or resident's, or the
19 person's or resident's surrogate decision maker's, refusal of
20 the administration of psychotropic medication, unless the
21 facility can demonstrate that the resident's refusal would
22 place the health and safety of the resident, the facility
23 staff, other residents, or visitors at risk.

24 A facility that alleges that the resident's refusal to
25 consent to the administration of psychotropic medication will
26 place the health and safety of the resident, the facility

1 staff, other residents, or visitors at risk must: (1) document
2 the alleged risk in detail; (2) present this documentation to
3 the resident or the resident's surrogate decision maker, to
4 the Department, and to the Office of the State Long Term Care
5 Ombudsman; and (3) inform the resident or his or her surrogate
6 decision maker of his or her right to appeal to the Department.
7 The documentation of the alleged risk shall include a
8 description of all nonpharmacological or alternative care
9 options attempted and why they were unsuccessful.

10 (b-15) Within 100 days after the effective date of any
11 rules adopted by the Department under subsection (b-3) ~~(b)~~ of
12 this Section, all facilities shall implement written policies
13 and procedures for compliance with this Section. When the
14 Department conducts its annual survey of a facility, the
15 surveyor may review these written policies and procedures and
16 either:

17 (1) give written notice to the facility that the
18 policies or procedures are sufficient to demonstrate the
19 facility's intent to comply with this Section; or

20 (2) provide written notice to the facility that the
21 proposed policies and procedures are deficient, identify
22 the areas that are deficient, and provide 30 days for the
23 facility to submit amended policies and procedures that
24 demonstrate its intent to comply with this Section.

25 A facility's failure to submit the documentation required
26 under this subsection is sufficient to demonstrate its intent

1 to not comply with this Section and shall be grounds for review
2 by the Department.

3 All facilities must provide training and education on the
4 requirements of this Section to all personnel involved in
5 providing care to residents and train and educate such
6 personnel on the methods and procedures to effectively
7 implement the facility's policies. Training and education
8 provided under this Section must be documented in each
9 personnel file.

10 (b-20) Upon the receipt of a report of any violation of
11 this Section, the Department shall investigate and, upon
12 finding sufficient evidence of a violation of this Section,
13 may proceed with disciplinary action against the licensee of
14 the facility. In any administrative disciplinary action under
15 this subsection, the Department shall have the discretion to
16 determine the gravity of the violation and, taking into
17 account mitigating and aggravating circumstances and facts,
18 may adjust the disciplinary action accordingly.

19 (b-25) A violation of informed consent that, for an
20 individual resident, lasts for 7 days or more under this
21 Section is, at a minimum, a Type "B" violation. A second
22 violation of informed consent within a year from a previous
23 violation in the same facility regardless of the duration of
24 the second violation is, at a minimum, a Type "B" violation.

25 (b-30) Any violation of this Section by a facility may be
26 enforced by an action brought by the Department in the name of

1 the People of Illinois for injunctive relief, civil penalties,
2 or both injunctive relief and civil penalties. The Department
3 may initiate the action upon its own complaint or the
4 complaint of any other interested party.

5 (b-35) Any resident who has been administered a
6 psychotropic medication in violation of this Section may bring
7 an action for injunctive relief, civil damages, and costs and
8 attorney's fees against any facility responsible for the
9 violation.

10 (b-40) An action under this Section must be filed within 2
11 years of either the date of discovery of the violation that
12 gave rise to the claim or the last date of an instance of a
13 noncompliant administration of psychotropic medication to the
14 resident, whichever is later.

15 (b-45) A facility subject to action under this Section
16 shall be liable for damages of up to \$500 for each day after
17 discovery of a violation that the facility violates the
18 requirements of this Section.

19 (b-55) The rights provided for in this Section are
20 cumulative to existing resident rights. No part of this
21 Section shall be interpreted as abridging, abrogating, or
22 otherwise diminishing existing resident rights or causes of
23 action at law or equity.

24 (c) The requirements of this Section are intended to
25 control in a conflict with the requirements of Sections 2-102
26 and 2-107.2 of the Mental Health and Developmental

1 Disabilities Code with respect to the administration of
2 psychotropic medication.

3 (d) In this Section only, "licensed nurse" means an
4 advanced practice registered nurse, a registered nurse, or a
5 licensed practical nurse.

6 (Source: P.A. 101-10, eff. 6-5-19; 102-646, eff. 8-27-21.)".